Bernstein Clinical Research Center Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2005
NCT00242359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bernstein Clinial Research Center | Bernstein Clinical Research Center | Jonathan A. Bernstein, MD

Active Ingredients

Drugs in Phase 4 Trials (3)

benralizumab (fasenra) (1 trial)

dupilumab (dupixent) (1 trial)

omalizumab (xolair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Dermatitis (Phase 4)

Dermatitis, Atopic (Phase 4)

Urticaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3